CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.

Shares of Moderna gain on positive clinical trial

By Robert Davis


Updated

Moderna vaccine
Moderna Covid-19 vaccine - Photo: Shutterstock

Shares of biotechnology company Moderna gained 1.58% on Wednesday after the company received positive clinical trial data regarding its Covid-19 vaccine.

The new analysis shows that Moderna’s vaccine presents greater protection against breakthrough infections - cases occurring in people who are fully vaccinated - than other vaccines, according to a press release.

Shares of Moderna finished Wednesday’s trading session at $434.46(£313.83) per share.

Clinical trial

The clinical trial was conducted in partnership with the US Center for Disease Control (CDC) and Kaiser Permanente.

It matched more than 350,000 individuals who were vaccinated against Covid-19 and an equal number of unvaccinated individuals and found Moderna’s vaccine is 87% effective at preventing infections and 96% effective at preventing hospitalizations.

The trial also found the vaccine to be 92% effective at preventing infections of the delta variant and 95% effective against all infections.

“It is promising to see clinical and real-world evidence adding to the growing body of data on the effectiveness of the Moderna Covid-19 vaccine,” Stéphane Bancel, CEO of Moderna, said in a statement.

“The increased risk of breakthrough infections in COVE study participants who were vaccinated last year compared to more recently illustrates the impact of waning immunity and supports the need for a booster to maintain high levels of protection,” he continued.

Oil - Crude

72.11 Price
-1.520% 1D Chg, %
Long position overnight fee -0.0146%
Short position overnight fee -0.0073%
Overnight fee time 21:00 (UTC)
Spread 0.03

Gold

1,944.05 Price
+0.010% 1D Chg, %
Long position overnight fee -0.0184%
Short position overnight fee 0.0102%
Overnight fee time 21:00 (UTC)
Spread 0.30

BTC/USD

27,822.70 Price
+0.170% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 60.00

XRP/USD

0.50 Price
+2.400% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.00426

Runaway winner

Over the past year, Moderna has been the runaway winner when compared to other vaccine manufacturers such as Pfizer and Johnson & Johnson.

In the past 12 months, shares of Moderna have increased more than 531% from $68.84 to more than $434 today.

In comparison, Pfizer's shares have increased 28% and Johnson & Johnson’s shares have risen 11% over the same period.

But, some analysts are concerned that the share value may be tied too closely to Covid-19.

According to a note from Trefis, Moderna’s continued investments in research and development is a key sign that Covid-19 may drive the shares going forward.

Doubly concerning is the increasing vaccination rate across the globe, the note argues. As vaccinations rise, shares may fall precipitously.

“Even if Covid-19 vaccine sales will continue for the foreseeable future, it’s likely that sales will show a declining trend versus 2021, as vaccination rates improve globally and as competition in the vaccine market mounts,” the note says.

Rate this article

Capital Com is an execution-only service provider. The material provided on this website is for information purposes only and should not be understood as an investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page then you do so entirely on your own risk.

Still looking for a broker you can trust?

Join the 530.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading